CapsoVision (NASDAQ:CV) Shares Up 12.9% – Still a Buy?

Shares of CapsoVision, Inc. (NASDAQ:CV) traded up 12.9% on Wednesday . The company traded as high as $14.69 and last traded at $14.56. 68,205 shares were traded during mid-day trading, a decline of 58% from the average session volume of 163,778 shares. The stock had previously closed at $12.90.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Roth Capital set a $7.00 price target on shares of CapsoVision in a report on Tuesday, November 4th. Zacks Research raised shares of CapsoVision to a “hold” rating in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of CapsoVision in a research report on Monday. Finally, Benchmark reiterated a “speculative buy” rating on shares of CapsoVision in a report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $6.00.

CapsoVision Trading Up 7.6%

The business’s 50-day moving average price is $7.18.

CapsoVision (NASDAQ:CV) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The firm had revenue of $3.54 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CapsoVision stock. New York State Common Retirement Fund acquired a new position in shares of CapsoVision, Inc. (NASDAQ:CV) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 7,114 shares of the company’s stock, valued at approximately $34,000.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.